



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification 5 :</b> <b>A21D 8/04</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 91/04669</b> <b>(43) International Publication Date:</b> 18 April 1991 (18.04.91)
<b>(21) International Application Number:</b> PCT/DK90/00244 <b>(22) International Filing Date:</b> 26 September 1990 (26.09.90) <b>(30) Priority data:</b> 4745/89 27 September 1989 (27.09.89) DK <b>(71) Applicant (for all designated States except US):</b> NOVO NORDISK A/S [DK/DK]; Novo Alle, DK-2880 Bagsvaerd (DK). <b>(72) Inventor; and</b> <b>(75) Inventor/Applicant (for US only) :</b> OLESEN, Tine [DK/DK]; Hagens Alle 57, DK-2900 Hellerup (DK). <b>(74) Agent:</b> Patent Department; Novo Nordisk A/S, Novo Alle, DK-2880 Bagsvaerd (DK).		<b>(81) Designated States:</b> AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent)*, DK (European patent), ES (European patent), FI, FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), NO, SE (European patent), US.  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> ANTISTALING PROCESS AND AGENT  <b>(57) Abstract</b>  The staling of leavened baked products such as bread is retarded by adding an enzyme with exoamylase activity to the flour or dough used for producing the baked product in question.		

### DESIGNATIONS OF "DE"

Until further notice, any designation of "DE" in any international application whose international filing date is prior to October 3, 1990, shall have effect in the territory of the Federal Republic of Germany with the exception of the territory of the former German Democratic Republic.

#### *FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MC	Monaco
AU	Australia	FI	Finland	MG	Madagascar
BB	Barbados	FR	France	ML	Mali
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Fasso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GR	Greece	NL	Netherlands
BJ	Benin	HU	Hungary	NO	Norway
BR	Brazil	IT	Italy	PL	Poland
CA	Canada	JP	Japan	RO	Romania
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
DE	Germany	LU	Luxembourg	TD	Chad
DK	Denmark			TG	Togo
				US	United States of America

## ANTISTALING PROCESS AND AGENT

## FIELD OF INVENTION

The present invention relates to a process for retarding the staling of bread and similar baked products, as well as an agent for use in the process.

## BACKGROUND OF THE INVENTION

Staling of baked products, principally bread, has been ascribed to certain properties of the starch component of flour. Starch is essentially composed of amylose forming the core of starch granules and amylopectin forming the outer "envelope" of starch granules. Starch suspensions have been observed to retrograde on standing to precipitate the amylose which, by some, has been given as the explanation of the phenomenon of staling. Others have explained staling of bread in terms of the amylopectin chains in starch associating to cause a greater rigidity of the bread crumb which is characteristic of stale bread.

It is generally recognized to be of some commercial importance to retard the staling of baked products so as to improve their shelf-life. Retardation of the staling process may, for instance, be brought about by the addition of monoglycerides to dough. The antistaling effect of the monoglycerides may partly be ascribed to their ability to bind water and partly to the formation of monoglyceride-amylose complexes wherein the long hydrocarbon chain penetrates into the cavity of the amylose helix and thereby stabilise the helical structure to prevent retrogradation.

Enzymatic retardation of staling by means of  $\alpha$ -amylases has also been described, vide for instance US 2,615,810 and US 3,026,205 as well as O. Silberstein, "Heat-Stable Bacterial

Alpha-Amylase in Baking", Baker's Digest 38(4), Aug. 1964, pp. 66-70 and 72. The use of  $\alpha$ -amylase for retarding the staling of bread has, however, not become widespread. The reason for this is assumed to be that the medium-molecular weight branched compounds, termed maltodextrins (with 20-100 glucose units in the molecule), generated through the hydrolytic action of  $\alpha$ -amylases have a sticky consistency in themselves resulting in the formation of a sticky or gummy crumb, and consequently an unacceptable mouthfeel, of the baked product if the  $\alpha$ -amylase is overdosed so that the maltodextrins are present in excessive quantities.

It has previously been suggested to remedy the deleterious effects of very large doses of  $\alpha$ -amylase added to dough by adding a debranching enzyme such as pullulanase, cf. US 4,654,216, the contents of which are incorporated herein by reference. The theory behind the addition of a debranching enzyme to obtain an antistaling effect while concomitantly avoiding the risk of producing a gummy crumb in the resulting bread is that by cleaving off the branched chains of the dextrins generated by  $\alpha$ -amylase hydrolysis which cannot be degraded further by the  $\alpha$ -amylase, the starch is converted to oligosaccharides which do not cause gumminess.

#### SUMMARY OF THE INVENTION

The present invention represents a different approach to the problem of crumb gumminess likely to result from the excessive use of  $\alpha$ -amylase for retarding the staling of bread. Thus, the present invention relies on the use of an enzyme which is capable of retarding the staling of baked products but which does not hydrolyze starch into the above-mentioned branched dextrins.

It has surprisingly been found that when the enzyme added to dough used for producing baked products is an exoamylase, an antistaling effect is obtained whereas the formation of a

sticky or gummy crumb is substantially avoided except at very high levels of the enzyme which also give rise to other deleterious effects likely to be discovered when the baked products are subjected to quality control.

- 5 It was also found that by using exoamylase enzymes one avoids a certain softness and stickiness of the dough which is often encountered when  $\alpha$ -amylases, especially fungal  $\alpha$ -amylases, are used for antistaling, and especially if the  $\alpha$ -amylase has been overdosed, even if only to a mild degree.
- 10 Accordingly, the present invention relates to a process for retarding the staling of leavened baked products, which process comprises adding an enzyme with exoamylase activity to flour or dough used for producing said baked products. In the following, this enzyme is usually referred to as an "exo-  
15 amylase".

In another aspect, the present invention relates to a baked product produced by the present process.

- It will often be advantageous to provide the exoamylase in admixture with other ingredients commonly used to improve the  
20 properties of baked products. These are commonly known as "pre-mixes" and are employed not only in industrial bread-baking plants/facilities, but also in retail bakeries where they are usually supplied in admixture with flour.

- Hence, in a further aspect, the present invention relates to  
25 an agent for improving the quality of leavened, in particular yeast leavened, baked products, which agent comprises an enzyme with exoamylase activity in liquid or substantially dry form. For the present purpose, such an agent will be termed a "bread improver" in the following description although it will  
30 be understood that it may also be used for addition to other types of leavened baked products such as rolls, certain kinds of cakes, muffins, buns, etc.

## DETAILED DISCLOSURE OF THE INVENTION

Exoamylases are enzymes which hydrolyse (1->4)  $\alpha$ -glucosidic linkages in starch (and related polysaccharides) by removing mono- or oligosaccharide units from the non-reducing ends of the polysaccharide chains. The reducing groups liberated from the polysaccharide molecule may be in the  $\alpha$ - or  $\beta$ -configuration. Examples of exoamylases which are useful for the present purpose are  $\beta$ -amylase (which releases maltose in the  $\beta$ -configuration) and maltogenic amylase (which releases maltose in the  $\alpha$ -configuration, but in contrast to  $\alpha$ -amylases predominantly produces maltotriose and maltotetraose and only minor amounts of higher oligosaccharides). The antistaling effect of adding exoamylase to dough is currently believed to be ascribable to the formation of sugars with a high water retention capacity which makes the baked product in question appear fresh (soft) for longer periods of time (e.g. glucose, maltose, maltotriose and/or maltotetraose), as well as to the modification of the native starch which reduces the tendency to retrogradation. Overdosing with the exoamylase resulting in crumb stickiness is less likely to occur because the formation of branched maltodextrins with 20-100 glucose units to which the stickiness may be ascribed is, if not completely avoided, at least significantly lower than when using  $\alpha$ -amylase.

The use of amylase (primarily  $\alpha$ -amylase), invertase and polysaccharidase, as well as glucosidase (an exoamylase)) is suggested in EP 136 158 and EP 136 159 for the preparation of cookies with a moist crumb structure. Amylase is capable of forming crystallization-resistant sugar, which is able to bind water, from one or more ingredients in the dough resulting in the aforementioned moist crumb when the dough is subsequently baked. The cookies are indicated to be storage-stable.

It appears that the selection of the enzyme according to EP 136 158 and EP 136 159 is made with the object of obtaining a

moist crumb structure due to the formation of water-binding sugars from starch. With this end in view, pregelatinized starch is added to the dough to facilitate enzymatic hydrolysis into various sugar species. It further appears that the risk of obtaining a gummy crumb in the baked product through addition of too large an amount of  $\alpha$ -amylase is not a problem to be avoided, but rather that moistness of the baked crumb is the end result which the inventions disclosed in the above-mentioned EP applications intend to achieve. In fact,  $\alpha$ -amylase which is known to produce crumb gumminess in leavened bread even when added in relatively low quantities is the preferred enzyme according to EP 136 159, the branched maltodextrins produced by the  $\alpha$ -amylase apparently providing satisfactory moisture characteristics to the cookies produced.

Contrary to this, the object of the present invention is to avoid a sticky or gummy crumb in the baked product. The principal difference between the baked products disclosed in the EP applications and those produced by the present process resides chiefly in the type of dough used to make the respective products. The products made by the present process are leavened which implies that the gluten in the dough which is composed of layers of protein "sheets" joined to bimolecular layers of lipo- and phospholipoproteins is expanded by the carbon dioxide produced by the leavening agent (e.g. yeast) into a thin film which coagulates to a firm structure on heating. Starch serves to make the structure firmer as, on heating, it solidifies within the gluten structure. Thus, when preparing leavened baked products including an amylase enzyme to provide the antistaling effect, care must be taken to select one which results in a hydrolysis product with a good water retention capacity (e.g. maltose, maltotriose and/or maltotetraose) and sufficient modification of the amylase and amylopectin to retard retrogradation so as to provide a longer-lasting softness of the baked product, without, however, excessively affecting the structure of the native starch. This seems to generate a hydrolysis product with a sticky consisten-

cy (e.g. the branched maltodextrins with 20-100 glucose units produced by  $\alpha$ -amylase) which would tend to impair this structure.

Consistent with the explanation given above, a preferred exo-  
5 amylase for use in the present process is one which exhibits exoamylase activity at and above the gelation temperature of starch (i.e. about 60-70 °C), as it has been found that the retrogradation of starch and consequently the precipitation of amylose responsible for staling takes place at this tem-  
10 perature. Another reason is that starch hydrolysis is facilitated when the starch is gelatinized such that the swelling of the starch granules caused by their uptake of liquid (water) liberated by the coagulation of gluten loosens the normally tight structure of the starch granules to make them more  
15 accessible to enzyme activity. This leads to a hydrolysis of the starch which is sufficient to retard retrogradation and to form adequate amounts of sugar without excessively modifying the native starch, resulting in an improved water retention. Contrary to such a heat-stable exoamylase, cereal  $\beta$ -amylases  
20 inherently present in flour exhibit little starch hydrolytic activity in the process of baking as they are inactive at the gelation temperature of starch. It should be noted that the exoamylases will be inactivated later in the baking process, at temperatures above about 90 °C so that substantially no  
25 residual exoamylase activity remains in the baked bread.

Preferred exoamylase enzymes are microbial exoamylases as these are easier to produce on a large scale than exoamylases of, for instance, plant origin. An example of a suitable exoamylase is a maltogenic amylase producible by Bacillus strain NCIB 11837,  
30 or one encoded by a DNA sequence derived from Bacillus strain NCIB 11837 (the maltogenic amylase is disclosed in US 4,598,048 and US 4,604,355, the contents of which are incorporated herein by reference) This maltogenic amylase is capable of hydrolyzing 1,4- $\alpha$ -glucosidic linkages in starch, partially hydrolyzed  
35 starch and oligosaccharides (e.g. maltotriose). Maltose units



are removed from the non-reducing chain ends in a stepwise manner. The maltose released is in the  $\alpha$ -configuration. In the US Patents mentioned above, the maltogenic amylase is indicated to be useful for the production of maltose syrup of a high 5 purity. Another maltogenic amylase which may be used in the present process is a maltogenic  $\beta$ -amylase producible by Bacillus strain NCIB 11608 (disclosed in EP 234 858, the contents of which are hereby incorporated by reference).

For the present purpose, this maltogenic amylase may be added 10 to flour or dough in an amount of 0.1-10,000 MANU, preferably 1-5000 MANU, more preferably 5-2000 MANU, and most preferably 10-1000 MANU, per kg of flour. One MANU (Maltogenic Amylase Novo Unit) may be defined as the amount of enzyme required to release one  $\mu$ mol of maltose per minute at a concentration of 10 15 mg of maltotriose (Sigma M 8378) substrate per ml of 0.1 M citrate buffer, pH 5.0 at 37 °C for 30 minutes.

The dough may be leavened in various ways such as by adding sodium bicarbonate or the like or by adding a leaven (fermenting dough), but it is preferred to leaven the dough by 20 adding a suitable yeast culture such as a culture of Saccharomyces cerevisiae (baker's yeast). Any one of the commercially available S. cerevisiae strains may be employed.

The baked product is generally one made from, or at least containing a certain amount of, wheat flour as such baked 25 products are more susceptible to staling than products made from, for instance, rye flour due to their airier structure. Thus, the baked product may be selected from the group consisting of white bread, whole-meal bread, and bread prepared from mixtures of wheat and rye flour. Of course rolls or the 30 like made from the same type of dough are also included in this definition.

In the present process, the exoamylase enzyme may be added to the dough in the form of a liquid, in particular a stabilized

liquid, or it may be added to flour or dough as a substantially dry powder or granulate. Granulates may be produced, e.g. as disclosed in US 4,106,991 and US 4,661,452. Liquid enzyme preparations may, for instance, be stabilized by adding a sugar or sugar alcohol or lactic acid according to established procedures. Other enzyme stabilizers are well-known in the art.

In accordance with established practice in the baking art, one or more other enzymes may be added to the flour or dough. 10 Examples of such enzymes are  $\alpha$ -amylase (useful for providing sugars fermentable by yeast although it should only be added in limited quantities, for the reasons given above), pentosanase (useful for the partial hydrolysis of pentosans which increases the extensibility of the dough) or a protease (useful 15 for gluten weakening, in particular when using hard wheat flour).

Also in accordance with established baking practice, one or more emulsifiers may be added to the flour or dough. Emulsifiers serve to improve dough extensibility and may also 20 be of some value for the consistency of the resulting bread, making it easier to slice, as well as for its storage stability, as explained above. Examples of suitable emulsifiers are mono- or diglycerides, polyoxyethylene stearates, diacetyl tartaric acid esters of monoglycerides, sugar esters of fatty 25 acids, propylene glycol esters of fatty acids, polyglycerol esters of fatty acids, lactic acid esters of monoglycerides, acetic acid esters of monoglycerides, lecithin or phospholipids.

When the bread improver of the invention is provided as a 30 substantially dry formulation, it will typically contain the exoamylase in substantially dry form. The enzyme may thus be in the form of a solid powder or granulate which may be prepared in a manner known per se as indicated above. The term "substantially dry formulation" should, in the present con-

text, be understood to mean that the formulation should appear as a dry and free-flowing powder and that the moisture content of the bread improver formulation should not exceed about 15%, and preferably not exceed about 10%. When the bread improver is 5 in the form of a semi-liquid preparation, the enzyme may also be incorporated in liquid form.

Apart from the exoamylase, the bread improver of the invention may typically comprise one or more components selected from the group consisting of milk powder (providing crust colour), 10 gluten (to improve the gas retention power of weak flours), an emulsifier (such as one of those mentioned above), granulated fat (for dough softening and consistency of bread), an oxidant (added to strengthen the gluten structure; e.g. ascorbic acid, potassium bromate, potassium iodate or ammonium persulfate), 15 another enzyme (e.g.  $\alpha$ -amylase, pentosanase or a protease as explained above), an amino acid (e.g. cysteine) and salt (e.g. sodium chloride, calcium acetate, sodium sulfate or calcium sulfate serving to make the dough firmer).

It is at present contemplated that the exoamylase may be 20 present in the bread improver in an amount of 1-5,000,000 MANU (as defined above) per kg of the bread improver, preferably 10-2,500,000 MANU, more preferably 50-1,000,000 MANU, most preferably 100-500,000 MANU, and in particular 1000-100,000 MANU of the exoamylase per kg of the bread improver. In 25 accordance with conventional practice for the use of bread improvers, this may be added to flour in an amount of 0.2-10%, in particular 0.5-5%, by weight of the flour.

The present invention is further illustrated in the following example which is not in any way intended to limit the scope 30 and spirit of the invention.

## EXAMPLE

White pan bread was prepared from the following ingredients

	Wheat flour*	100%
	Water	52%
5	Sodium chloride	2%
	Baker's yeast	2.5%

\*) commercial wheat flour of moderate quality (treated with ascorbic acid):  
≈ 11% protein, ≈ 15% humidity

10 by mixing with a spiral mixer for 4 minutes at 140 rpm and for 3 minutes at 280 rpm (Speed of the spiral rotor). The dough temperature was 26°C. The dough was allowed to rise for 40 minutes at 34°C and, after degassing and moulding, for 65 minutes at 34°C. The bread was subsequently baked for 30 minutes at 230°C.

To the dough ingredients were added varying amounts of NOVAMYL™ (a recombinant maltogenic amylase encoded by a DNA sequence derived from Bacillus strain NCIB 11837, described in US 4,598,048), Fungamyl 1600 S (a commercial α-amylase available from Novo-Nordisk a/s) and Veron F25 (a commercial α-amylase available from Röhm), respectively. The results appear from the following tables.

Table 1

NOVAMYL™, 1500 MANU/g

5

Dosage in g/100kg of flour

0	6.7	13.3	27	53	107
---	-----	------	----	----	-----

## Properties

10	Dough	short struc- ture	short struc- ture	short struc- ture	short struc- ture	short struc- ture	short struc- ture
	Volume index	100	99	99	100	100	101
15	Crumb structure	fine	fine	fine			coarser
	Crumb freshness (48 h)	100	240	270	280	310	310
20	Crumb freshness (72 h)	100	160	200	230	270	270
	Crumb freshness (96 h)	100	160	390	425	500	580
25	Gummy crumb	no	no	no	no	no	yes

Table 2

Fungamyl™ 1600 S

Dosage in g/100kg of flour

5		Dosage in g/100kg of flour					
		0	10	20	40	80	160
Properties							
10	Dough	short	pos.	pos.	dough	dough	dough
		struc- ture			too soft	too soft	too soft
	Volume index	100	102	107	107	106	106
15	Crumb structure	fine	fine/ ripe	fine/			coarser
		ripe					
	Crumb freshness (48 h)	100	240	280	290	330	320
20	Crumb freshness (72 h)	100	145	240	230	280	290
25	Crumb freshness (96 h)	100	200	250	530	650	675
	Gummy crumb	no	no	no	no/yes	yes	yes

Table 3

Veron F25

		Dosage in g/100kg of flour					
		0	10	20	40	80	106
Properties							
	Dough	short struc- ture	pos.	pos.	pos.	pos.	pos.
10	Volume index	100	100	100	102	102	102
	Crumb structure	fine	fine	fine			coarser
15	Crumb freshness (48 h)	100	210	210	210	235	210
20	Crumb freshness (72 h)	100	125	125			230
	Crumb freshness (96 h)						
25	Gummy crumb	no	no	no	no/yes	yes	yes

It appears from the tables above that, compared to the use of Fungamyl 1600 S and Veron F25, the addition of NOVAMYL™ to dough leads to improved storage properties of the resulting bread without a concomitant gumminess of the crumb which only occurs a far larger dosage of the enzyme. NOVAMYL™ does not significantly change other dough or bread characteristics.

## CLAIMS

1. A process for retarding the staling of leavened baked products comprising adding an enzyme with exoamylase activity to flour or dough.
- 5 2. A process according to claim 1, wherein the enzyme with exoamylase activity is a  $\beta$ -amylase or maltogenic amylase.
3. A process according to claim 1, wherein enzyme is one exhibiting activity at and above the gelation temperature of starch.
- 10 4. A process according to claim 1, wherein the enzyme is a microbial exoamylase.
5. A process according to claim 2 or 4, wherein the maltogenic amylase is one producible by Bacillus strain NCIB 11837, or one encoded by a DNA sequence derived from Bacillus strain NCIB  
15 11837.
6. A process according to claim 5, wherein the enzyme is added in an amount of 0.1-10,000 MANU (as defined herein) per kg of flour.
7. A process according to claim 6, wherein the enzyme is added  
20 in an amount of 1-5000 MANU, preferably 5-2000 MANU, and most preferably 10-1000 MANU, per kg of flour.
8. A process according to claim 1, wherein a suitable yeast culture is added to the dough.
9. A process according to claim 1, wherein the baked product  
25 is white bread, whole-meal bread, or bread produced from mixtures of wheat and rye flour.



10. A process according to claim 1, wherein one or more other enzymes are added to the flour or dough.
11. A process according to claim 10, wherein the other enzyme(s) is/are  $\alpha$ -amylase, pentosanase or a protease.
- 5 12. A process according to claim 1, wherein one or more emulsifiers are added to the flour or dough.
13. A process according to claim 12, wherein the emulsifier(s) is/are mono- or diglycerides, polyoxyethylene stearates, diacetyl tartaric acid esters of monoglycerides, sugar esters  
10 of fatty acids, propylene glycol esters of fatty acids, polyglycerol esters of fatty acids, lactic acid esters of monoglycerides, acetic acid esters of monoglycerides, lecithin or phospholipids.
14. A baked product produced by the process according to any  
15 of claims 1-13.
15. An agent for improving the quality of leavened baked products, which agent comprises an enzyme with exoamylase activity in liquid or substantially dry form.
16. An agent according to claim 15, wherein the enzyme with  
20 exoamylase activity is a glucoamylase,  $\beta$ -amylase or maltogenic amylase.
17. An agent according to claim 15, wherein enzyme is one exhibiting activity at the gelation temperature of starch.
18. An agent according to claim 15 or 16, wherein the enzyme  
25 is a microbial exoamylase.

19. An agent according to claim 18, wherein the maltogenic amylase is one producible by Bacillus strain NCIB 11837, or one encoded by a DNA sequence derived from Bacillus strain NCIB 11837.

5 20. An agent according to any of claims 15-19, which further comprises one or more components selected from the group consisting of milk powder, gluten, an emulsifier, granulated fat, an oxidant (e.g. ascorbic acid, potassium bromate, potassium iodate or ammonium persulfate), another enzyme (e.g.  $\alpha$ -amylase,  
10 pentosanase or a protease), an amino acid (e.g. cystein) and a salt (e.g. sodium chloride, calcium acetate, sodium sulfate or calcium sulfate).

# INTERNATIONAL SEARCH REPORT

International Application No PCT/DK 90/00244

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (if several classification symbols apply, indicate all) <sup>6</sup> According to International Patent Classification (IPC) or to both National Classification and IPC <b>IPC5: A 21 D 8/04</b>																							
<b>II. FIELDS SEARCHED</b> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black;">Minimum Documentation Searched<sup>7</sup></div> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; border-bottom: 1px solid black;">Classification System</td> <td style="border-bottom: 1px solid black;">Classification Symbols</td> </tr> <tr> <td style="height: 40px; vertical-align: bottom;">IPC5</td> <td style="vertical-align: bottom;">A 21 D</td> </tr> </table> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in Fields Searched<sup>8</sup></div> <p style="padding: 5px;">SE,DK,FI,NO classes as above</p>			Classification System	Classification Symbols	IPC5	A 21 D																	
Classification System	Classification Symbols																						
IPC5	A 21 D																						
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>9</sup></b> <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 10%; border-bottom: 1px solid black;">Category *</th> <th style="width: 60%; border-bottom: 1px solid black;">Citation of Document,<sup>11</sup> with indication, where appropriate, of the relevant passages<sup>12</sup></th> <th style="width: 30%; border-bottom: 1px solid black;">Relevant to Claim No.<sup>13</sup></th> </tr> <tr> <td style="vertical-align: top; text-align: center;">X</td> <td style="vertical-align: top;">Chemical Abstracts, volume 107, no. 5, 3 August 1987, (Columbus, Ohio, US), see page 576, abstract 38380q, &amp; JP,, 6279745 (Okada, Shigetaka et al) 1987</td> <td style="vertical-align: top; text-align: center;">1-4,6-18,20</td> </tr> <tr> <td style="vertical-align: top; text-align: center;">Y</td> <td style="vertical-align: top; text-align: center;">--</td> <td style="vertical-align: top; text-align: center;">5,19</td> </tr> <tr> <td style="vertical-align: top; text-align: center;">X</td> <td style="vertical-align: top;">Chemical Abstracts, volume 107, no. 5, 3 August 1987, (Columbus, Ohio, US), see page 576, abstract 38381r, &amp; JP,, 6279746 (Okada, Shigetaka et al) 1987</td> <td style="vertical-align: top; text-align: center;">1-4,6-18,20</td> </tr> <tr> <td style="vertical-align: top; text-align: center;">Y</td> <td style="vertical-align: top; text-align: center;">--</td> <td style="vertical-align: top; text-align: center;">5,19</td> </tr> <tr> <td style="vertical-align: top; text-align: center;">X</td> <td style="vertical-align: top;">EP, A2, 0171995 (KYOWA HAKKO KOGYO CO., LTD.) 19 February 1986, see pages 2 and 3</td> <td style="vertical-align: top; text-align: center;">1-3,6-17,20</td> </tr> <tr> <td style="vertical-align: top; text-align: center;">Y</td> <td style="vertical-align: top; text-align: center;">--</td> <td style="vertical-align: top; text-align: center;">4-5,18-19</td> </tr> </table>			Category *	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>	X	Chemical Abstracts, volume 107, no. 5, 3 August 1987, (Columbus, Ohio, US), see page 576, abstract 38380q, & JP,, 6279745 (Okada, Shigetaka et al) 1987	1-4,6-18,20	Y	--	5,19	X	Chemical Abstracts, volume 107, no. 5, 3 August 1987, (Columbus, Ohio, US), see page 576, abstract 38381r, & JP,, 6279746 (Okada, Shigetaka et al) 1987	1-4,6-18,20	Y	--	5,19	X	EP, A2, 0171995 (KYOWA HAKKO KOGYO CO., LTD.) 19 February 1986, see pages 2 and 3	1-3,6-17,20	Y	--	4-5,18-19
Category *	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>																					
X	Chemical Abstracts, volume 107, no. 5, 3 August 1987, (Columbus, Ohio, US), see page 576, abstract 38380q, & JP,, 6279745 (Okada, Shigetaka et al) 1987	1-4,6-18,20																					
Y	--	5,19																					
X	Chemical Abstracts, volume 107, no. 5, 3 August 1987, (Columbus, Ohio, US), see page 576, abstract 38381r, & JP,, 6279746 (Okada, Shigetaka et al) 1987	1-4,6-18,20																					
Y	--	5,19																					
X	EP, A2, 0171995 (KYOWA HAKKO KOGYO CO., LTD.) 19 February 1986, see pages 2 and 3	1-3,6-17,20																					
Y	--	4-5,18-19																					
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>* Special categories of cited documents: <sup>10</sup></p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&amp;" document member of the same patent family</p> </div> </div>																							
<b>IV. CERTIFICATION</b> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; border-bottom: 1px solid black;">Date of the Actual Completion of the International Search</td> <td style="width: 50%; border-bottom: 1px solid black;">Date of Mailing of this International Search Report</td> </tr> <tr> <td style="height: 40px; vertical-align: bottom;">19th December 1990</td> <td style="vertical-align: bottom; text-align: center;">1991 -01- 02</td> </tr> <tr> <td style="border-bottom: 1px solid black;">International Searching Authority</td> <td style="border-bottom: 1px solid black;">Signature of Authorized Officer</td> </tr> <tr> <td style="text-align: center; vertical-align: bottom;">SWEDISH PATENT OFFICE</td> <td style="text-align: center; vertical-align: bottom;">            Kerstin Boije Janson         </td> </tr> </table>			Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	19th December 1990	1991 -01- 02	International Searching Authority	Signature of Authorized Officer	SWEDISH PATENT OFFICE	Kerstin Boije Janson													
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report																						
19th December 1990	1991 -01- 02																						
International Searching Authority	Signature of Authorized Officer																						
SWEDISH PATENT OFFICE	Kerstin Boije Janson																						

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
Y	US, A, 4598048 (DIDERICHSEN ET AL) 1 July 1986, see abstract --	5,19
X	Allan Himmelstein "Enzyme treatment of flour", 1984, Bakers Digest, New York, see Fig 2 and 5 --	1-4,6- 18,20
X	EP, A2, 0154135 (LIEKEN-BATSCHIEDER MÜHLEN- UND BACKBETRIEBE GMBH) 11 September 1985, see page 3, 3:rd col. -- -----	1-2,8- 16,20

# ANNEX TO THE INTERNATIONAL SEARCH REPORT ON INTERNATIONAL PATENT APPLICATION NO.PCT/DK 90/00244

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.  
The members are as contained in the Swedish Patent Office EDP file on 90-11-28  
The Swedish Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A2- 0171995	86-02-19	CA-A- 1262654	89-11-07
		JP-A- 61047133	86-03-07
		JP-A- 61056037	86-03-20
US-A- 4598048	86-07-01	CA-A- 1214407	86-11-25
		EP-A-B- 0120693	84-10-03
		JP-A- 60002185	85-01-08
		US-A- 4604355	86-08-05
EP-A2- 0154135	85-09-11	DE-A-C- 3402778	85-08-08
		DE-A- 3437789	86-04-17